Amplification-free CRISPR/Cas13a-based electrochemical biosensor for the detection of circulating tumor RNA using RNA-3Ag⁺ probes on Au porous-lattice nanoelectrode.
[UNLABELLED] Circulating tumor RNA (ctRNA) is a sensitive biomarker for early cancer diagnosis, offering real-time gene expression profiles and tumor-specific signatures missed by circulating tumor DN
APA
Lee YR, Lee MJ, et al. (2026). Amplification-free CRISPR/Cas13a-based electrochemical biosensor for the detection of circulating tumor RNA using RNA-3Ag⁺ probes on Au porous-lattice nanoelectrode.. Journal of biological engineering, 20(1). https://doi.org/10.1186/s13036-026-00641-0
MLA
Lee YR, et al.. "Amplification-free CRISPR/Cas13a-based electrochemical biosensor for the detection of circulating tumor RNA using RNA-3Ag⁺ probes on Au porous-lattice nanoelectrode.." Journal of biological engineering, vol. 20, no. 1, 2026.
PMID
41731584
Abstract
[UNLABELLED] Circulating tumor RNA (ctRNA) is a sensitive biomarker for early cancer diagnosis, offering real-time gene expression profiles and tumor-specific signatures missed by circulating tumor DNA. Despite its potential, a simple, rapid, and sensitive ctRNA detection sensor has not yet been developed. For the first time, we present an amplification-free electrochemical biosensor for ctRNA detection by integrating the CRISPR/Cas13a system with a silver ion (Ag⁺)-mediated RNA probe and an Au porous-lattice nanoelectrode (APLNE). A three-cytosine-cytosine (C–C) mismatched RNA duplex was employed as a signal probe, allowing site-specific Ag⁺ intercalation to form stable C–Ag⁺–C coordination complexes (RNA-3Ag⁺) that generate strong redox peaks. To further enhance performance, the APLNE, featuring a highly aligned porous gold nanostructure, was used to increase the effective surface area, improving probe immobilization and electrochemical signals. Upon target recognition, CRISPR/Cas13a cleaved the RNA-3Ag⁺ probe, resulting in a significant signal reduction. This biosensor detects KRAS G12D ctRNA, a key pancreatic cancer mutation, with ultrahigh sensitivity (LOD = 0.5 fM) in just 20 min and demonstrates excellent specificity in complex biological samples. Operating without nucleic acid amplification or toxic redox reagents, this simple, cost-effective, and eco-friendly platform shows strong potential for liquid biopsy-based diagnostics and point-of-care cancer screening.
[GRAPHICAL ABSTRACT] [Image: see text]
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s13036-026-00641-0.
[GRAPHICAL ABSTRACT] [Image: see text]
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s13036-026-00641-0.
같은 제1저자의 인용 많은 논문 (5)
- Association Between Tumor Size and Nodal Positivity for HER2+ and Triple-Negative Early-Stage Breast Cancer: A Population-Based Study.
- ASO Visual Abstract: Association Between Tumor Size and Nodal Positivity for HER2+ and Triple-Negative Early-Stage Breast Cancer: A Population-Based Study.
- Liver Stiffness Measurements After Oral Antivirals Effectively Predict the Risk of HCC in Patients With Chronic Hepatitis C.
- Increased intraocular pressure after extensive conjunctival removal: a case report.
- Hair restoration surgery in patients with pubic atrichosis or hypotrichosis: review of technique and clinical consideration of 507 cases.